Target intelligence / Profile preview

N-linked terminal galactose residues on cell-surface glycans (Terminal Gal)

Target
Terminal Gal
Molecular classification
Glycan, Carbohydrate, Post-translational modification, Other
01

Overview

N-linked terminal galactose residues are carbohydrate structures found at the distal ends of N-glycan chains on cell-surface and secreted glycoproteins. These residues are typically masked by terminal sialic acids; their exposure, often termed desialylation, serves as a key biological signal for protein turnover and cell-cell interactions (Stockert, 1995). The primary physiological receptor for these residues is the Ashwell-Morell receptor (asialoglycoprotein receptor, ASGPR) located on hepatocytes, which facilitates the endocytosis and degradation of desialylated proteins (Ashwell & Harford, 1982). In pathological contexts, such as cancer, aberrant glycosylation leads to the overexposure of terminal galactose, which can promote metastasis by interacting with galectins or facilitate immune evasion (Pinho & Reis, 2015). From a pharmacological perspective, terminal galactose residues are targeted for liver-specific drug delivery systems and are the binding targets for potent toxins like ricin, as well as various diagnostic lectins (Lord et al., 2003).

Other names
Terminal beta-galactoseAsialoglycansGalactose-terminated N-glycansTerminal Gal residuesAsialoglycoprotein receptor ligand
02

Mechanism of action

Binding to asialoglycoprotein receptors (ASGPR) for hepatic clearance, or interaction with galectins to modulate cell signaling and adhesion (Stockert, 1995; Johannes et al., 2018).

03

Biological functions

Signal transductionImmune responseOther
04

Disease associations

CancerInfectionOther
05

Safety considerations

Rapid hepatic clearance of therapeutic proteins (Ashwell & Harford, 1982)Off-target binding in the liverPotential for systemic toxicity with lectin-based conjugates (Lord et al., 2003)
06

Interacting drugs

Ricin

3 more in the full profile.

07

Biomarkers

Asialoglycoprotein levels (Stockert, 1995)Serum glycan profile (Pinho & Reis, 2015)Galectin-3 levels (Johannes et al., 2018)

Beyond the preview

Go deeper on N-linked terminal galactose residues on cell-surface glycans (Terminal Gal).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-linked terminal galactose residues on cell-surface glycans (Terminal Gal).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call